Somatostatin receptor PET/CT using 68 Ga-labeled somatostatin analogs, is a mainstay for
the evaluation of the somatostatin receptor status in neuroendocrine neoplasms. In addition,
the assessment of glucose metabolism by 18 F-FDG PET/CT at diagnosis can overcome
probable shortcomings of histopathologic grading. This offers a systematic theranostic
approach for the management of neuroendocrine neoplasms, that is, patient selection for the
appropriate treatment—surgery, somatostatin analogs, peptide receptor radionuclide …